These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 29246309)

  • 1. Fine and Predictable Tuning of TALEN Gene Editing Targeting for Improved T Cell Adoptive Immunotherapy.
    Gautron AS; Juillerat A; Guyot V; Filhol JM; Dessez E; Duclert A; Duchateau P; Poirot L
    Mol Ther Nucleic Acids; 2017 Dec; 9():312-321. PubMed ID: 29246309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies.
    Poirot L; Philip B; Schiffer-Mannioui C; Le Clerre D; Chion-Sotinel I; Derniame S; Potrel P; Bas C; Lemaire L; Galetto R; Lebuhotel C; Eyquem J; Cheung GW; Duclert A; Gouble A; Arnould S; Peggs K; Pule M; Scharenberg AM; Smith J
    Cancer Res; 2015 Sep; 75(18):3853-64. PubMed ID: 26183927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimized tuning of TALEN specificity using non-conventional RVDs.
    Juillerat A; Pessereau C; Dubois G; Guyot V; Maréchal A; Valton J; Daboussi F; Poirot L; Duclert A; Duchateau P
    Sci Rep; 2015 Jan; 5():8150. PubMed ID: 25632877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Automated generation of gene-edited CAR T cells at clinical scale.
    Alzubi J; Lock D; Rhiel M; Schmitz S; Wild S; Mussolino C; Hildenbeutel M; Brandes C; Rositzka J; Lennartz S; Haas SA; Chmielewski KO; Schaser T; Kaiser A; Cathomen T; Cornu TI
    Mol Ther Methods Clin Dev; 2021 Mar; 20():379-388. PubMed ID: 33575430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TALEN-edited allogeneic inducible dual CAR T cells enable effective targeting of solid tumors while mitigating off-tumor toxicity.
    Dharani S; Cho H; Fernandez JP; Juillerat A; Valton J; Duchateau P; Poirot L; Das S
    Mol Ther; 2024 Nov; 32(11):3915-3931. PubMed ID: 39169622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing.
    Jo S; Das S; Williams A; Chretien AS; Pagliardini T; Le Roy A; Fernandez JP; Le Clerre D; Jahangiri B; Chion-Sotinel I; Rozlan S; Dessez E; Gouble A; Dusséaux M; Galetto R; Duclert A; Marcenaro E; Devillier R; Olive D; Duchateau P; Poirot L; Valton J
    Nat Commun; 2022 Jun; 13(1):3453. PubMed ID: 35773273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimized two-step electroporation process to achieve efficient nonviral-mediated gene insertion into primary T cells.
    Yang M; Tkach D; Boyne A; Kazancioglu S; Duclert A; Poirot L; Duchateau P; Juillerat A
    FEBS Open Bio; 2022 Jan; 12(1):38-50. PubMed ID: 34510816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-viral expression of chimeric antigen receptors with multiplex gene editing in primary T cells.
    Cappabianca D; Li J; Zheng Y; Tran C; Kasparek K; Mendez P; Thu R; Maures T; Capitini CM; Deans R; Saha K
    Front Bioeng Biotechnol; 2024; 12():1379900. PubMed ID: 38882639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy.
    Liu X; Zhao Y
    Curr Res Transl Med; 2018 May; 66(2):39-42. PubMed ID: 29691200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR T cells.
    Sasu BJ; Opiteck GJ; Gopalakrishnan S; Kaimal V; Furmanak T; Huang D; Goswami A; He Y; Chen J; Nguyen A; Balakumaran A; Shah NN; Hamadani M; Bone KM; Prashad S; Bowen MA; Pertel T; Embree HD; Gidwani SG; Chang D; Moore A; Leonard M; Amado RG
    Mol Ther; 2023 Mar; 31(3):676-685. PubMed ID: 36518079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological interventions enhance virus-free generation of
    Kath J; Du W; Pruene A; Braun T; Thommandru B; Turk R; Sturgeon ML; Kurgan GL; Amini L; Stein M; Zittel T; Martini S; Ostendorf L; Wilhelm A; Akyüz L; Rehm A; Höpken UE; Pruß A; Künkele A; Jacobi AM; Volk HD; Schmueck-Henneresse M; Stripecke R; Reinke P; Wagner DL
    Mol Ther Methods Clin Dev; 2022 Jun; 25():311-330. PubMed ID: 35573047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Universal CARs, universal T cells, and universal CAR T cells.
    Zhao J; Lin Q; Song Y; Liu D
    J Hematol Oncol; 2018 Nov; 11(1):132. PubMed ID: 30482221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.
    Eyquem J; Mansilla-Soto J; Giavridis T; van der Stegen SJ; Hamieh M; Cunanan KM; Odak A; Gönen M; Sadelain M
    Nature; 2017 Mar; 543(7643):113-117. PubMed ID: 28225754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.
    Hu B; Zou Y; Zhang L; Tang J; Niedermann G; Firat E; Huang X; Zhu X
    Hum Gene Ther; 2019 Apr; 30(4):446-458. PubMed ID: 29706119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of gene editing efficiencies of CRISPR/Cas9 and TALEN for generation of MSTN knock-out cashmere goats.
    Zhang J; Liu J; Yang W; Cui M; Dai B; Dong Y; Yang J; Zhang X; Liu D; Liang H; Cang M
    Theriogenology; 2019 Jul; 132():1-11. PubMed ID: 30981084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene Augmentation and Editing to Improve TCR Engineered T Cell Therapy against Solid Tumors.
    Lo Presti V; Buitenwerf F; van Til NP; Nierkens S
    Vaccines (Basel); 2020 Dec; 8(4):. PubMed ID: 33287413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TALEN-mediated genome-editing approaches in the liverwort
    Kopischke S; Schüßler E; Althoff F; Zachgo S
    Plant Methods; 2017; 13():20. PubMed ID: 28360929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of Stable Knockout Mammalian Cells by TALEN-Mediated Locus-Specific Gene Editing.
    Mahata B; Biswas K
    Methods Mol Biol; 2017; 1498():107-120. PubMed ID: 27709571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells.
    MacLeod DT; Antony J; Martin AJ; Moser RJ; Hekele A; Wetzel KJ; Brown AE; Triggiano MA; Hux JA; Pham CD; Bartsevich VV; Turner CA; Lape J; Kirkland S; Beard CW; Smith J; Hirsch ML; Nicholson MG; Jantz D; McCreedy B
    Mol Ther; 2017 Apr; 25(4):949-961. PubMed ID: 28237835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.